AstraZeneca and Merck Announce US FDA Accept Submission of sNDA for LYNPARZA® (olaparib) and Grants Priority Review

AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that a supplemental New Drug Application (sNDA) for LYNPARZA has been accepted and granted priority review by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations, who have progressed following prior treatment with a new hormonal agent.

A Prescription Drug User Fee Act (PDUFA) date is set for the second quarter of 2020.

The sNDA acceptance for review by the FDA is based on positive results from the Phase 3 PROfound trial, which were presented during a Presidential Symposium at the 2019 European Society of Medical Oncology congress.

Results of the PROfound trial showed LYNPARZA met its primary endpoint, significantly reducing the risk of radiographic disease progression or death by 66% in patients with BRCA1/2 or ATM-mutated mCRPC and improved radiographic progression-free survival (rPFS) to a median of 7.4 months vs. 3.6 months for patients receiving abiraterone or enzalutamide (HR 0.34 [95% CI, 0.25-0.47], p<0.0001).

The trial also met the key secondary endpoint of rPFS in the overall population of men with HRR-mutated (HRRm) mCRPC (those with mutations in BRCA1/2, ATM, CDK12 or 11 other HRRm genes), where LYNPARZA reduced the risk of radiographic disease progression or death by 51% and improved rPFS to a median of 5.8 months vs. 3.5 months for those receiving abiraterone or enzalutamide (HR 0.49 [95% CI, 0.38-0.63], p<0.0001).

The safety and tolerability profile of LYNPARZA in the PROfound trial did not differ from that observed in prior clinical trials. The most common adverse events (AEs) ≥20% for LYNPARZA compared to abiraterone or enzalutamide were anemia (47% vs.15%), nausea (41% vs. 19%), fatigue and asthenia (41% vs. 32%), decreased appetite (30% vs. 18%) and diarrhea (21% vs. 7%). Grade 3 or above AEs were anemia (22% vs. 5%), fatigue and asthenia (3% vs. 5%), vomiting (2% vs. 1%), dyspnea (2% vs. 0%), urinary tract infection (2% vs. 4%), nausea (1% vs. 0%), decreased appetite (1% each), diarrhea (1% vs. 0%) and back pain (1% vs. 2%). AEs led to dose interruptions in 22% of patients on LYNPARZA vs. 4% of patients on abiraterone and enzalutamide and discontinuation of treatment in 16% of patients on LYNPARZA vs. 9% on abiraterone and enzalutamide.

PROfound is the first Phase 3 trial evaluating a targeted treatment in biomarker-selected prostate cancer patients. LYNPARZA, which is being jointly developed and commercialized by AstraZeneca and Merck, was most recently approved in the U.S. on Dec. 27, 2019, as a first-line maintenance treatment for germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer that has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. It is also approved in the U.S. as a first-line maintenance treatment in BRCA-mutated advanced ovarian cancer following response to platinum-based chemotherapy and for the treatment of gBRCAm HER2-negative metastatic breast cancer patients previously treated with chemotherapy.



Related Topics and Keywords

,

Subscribe to our FREE newsletter

We will not sell or give your information to a third party. See our Privacy Policy